Search Results - Mika K. Derynck

  • Showing 1 - 11 results of 11
Refine Results
  1. 1
    Chromatin immunoprecipitation (ChIP) scanning identifies primary glucocorticoid receptor target genes

    Chromatin immunoprecipitation (ChIP) scanning identifies primary glucocorticoid receptor target genes by Jen-Chywan Wang, Mika K. Derynck, Daisuke Nonaka, Daniel Khodabakhsh, Chris Haqq, Keith R. Yamamoto

    Published 2004
    Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    Activation of Stem‐Cell Specific Genes by HOXA9 and HOXA10 Homeodomain Proteins in CD34<sup>+</sup>Human Cord Blood Cells

    Activation of Stem‐Cell Specific Genes by HOXA9 and HOXA10 Homeodomain Proteins in CD34<sup>+</sup>Human Cord Blood Cells by Christina M. Ferrell, Sheri T. Dorsam, Hideaki Ohta, R. Keith Humphries, Mika K. Derynck, Chris Haqq, Corey Largman, H. Jeffrey Lawrence

    Published 2005
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Target-specific utilization of transcriptional regulatory surfaces by the glucocorticoid receptor

    Target-specific utilization of transcriptional regulatory surfaces by the glucocorticoid receptor by Inez Rogatsky, Jen-Chywan Wang, Mika K. Derynck, Daisuke Nonaka, Daniel Khodabakhsh, Christopher M. Haqq, Beatrice Darimont, Michael J. Garabedian, Keith R. Yamamoto

    Published 2003
    Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    The transcriptome of the leukemogenic homeoprotein HOXA9 in human hematopoietic cells

    The transcriptome of the leukemogenic homeoprotein HOXA9 in human hematopoietic cells by Sheri T. Dorsam, Christina M. Ferrell, Glenn Dorsam, Mika K. Derynck, Ulka Vijapurkar, Daniel Khodabakhsh, Bonnie Pau, Hillary Bernstein, Christopher M. Haqq, Corey Largman, H. Jeffrey Lawrence

    Published 2003
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Prospective, Multicenter, Randomized Phase II Trial of the Herbal Supplement, PC-SPES, and Diethylstilbestrol in Patients With Androgen-Independent Prostate Cancer

    Prospective, Multicenter, Randomized Phase II Trial of the Herbal Supplement, PC-SPES, and Diethylstilbestrol in Patients With Androgen-Independent Prostate Cancer by William Oh, Philip W. Kantoff, Vivian Weinberg, Graham Jones, Brian I. Rini, Mika K. Derynck, Robert Bok, Matthew Ryan Smith, Glenn J. Bubley, Robert T. Rosen, Robert S. DiPaola, Eric J. Small

    Published 2004
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Efficacy and Safety of Single-Agent Pertuzumab (rhuMAb 2C4), a Human Epidermal Growth Factor Receptor Dimerization Inhibitor, in Castration-Resistant Prostate Cancer After Progression From Taxane-Based Therapy

    Efficacy and Safety of Single-Agent Pertuzumab (rhuMAb 2C4), a Human Epidermal Growth Factor Receptor Dimerization Inhibitor, in Castration-Resistant Prostate Cancer After Progress... by David B. Agus, Christopher J. Sweeney, Michael J. Morris, David S. Mendelson, Douglas G. McNeel, Frederick R. Ahmann, Jin Wang, Mika K. Derynck, Kimmie Ng, Benjamin Lyons, David E. Allison, Michael W. Kattan, Howard I. Scher

    Published 2007
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant

    Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant by Jill M. Spoerke, Steven Gendreau, Kimberly Walter, Jiaheng Qiu, Timothy R. Wilson, Heidi Savage, Junko Aimi, Mika K. Derynck, Meng Chen, Iris T. Chan, Lukas C. Amler, Garret M. Hampton, Stephen Johnston, Ian E. Krop, Peter Schmid, Mark R. Lackner

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors

    Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors by Fiore Cattaruzza, Ayesha Nazeer, Milton To, Mikhail Hammond, Caitlin Koski, Lucas Y. Liu, V. Pete Yeung, Deena A. Rennerfeldt, Angela Henkensiefken, Michael Fox, Sharon Lam, Kari M. Morrissey, Zachary Lange, Vladimir N. Podust, Mika K. Derynck, Bryan Irving, Volker Schellenberger

    Published 2023
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Clinical Activity of Pertuzumab (rhuMAb 2C4), a HER Dimerization Inhibitor, in Advanced Ovarian Cancer: Potential Predictive Relationship With Tumor HER2 Activation Status

    Clinical Activity of Pertuzumab (rhuMAb 2C4), a HER Dimerization Inhibitor, in Advanced Ovarian Cancer: Potential Predictive Relationship With Tumor HER2 Activation Status by Michael S. Gordon, Daniela Matei, Carol Aghajanian, Ursula A. Matulonis, Molly Brewer, Gini F. Fleming, John D. Hainsworth, Agustin A. García, Mark D. Pegram, Russell J. Schilder, David E. Cohn, Lynda D. Roman, Mika K. Derynck, Kimmie Ng, Benjamin Lyons, David E. Allison, David A. Eberhard, Thinh Q. Pham, Randall C. Dere, Beth Y. Karlan

    Published 2006
    Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors

    First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors by Debashis Sarker, Joo Ern Ang, Richard D. Baird, Rebecca Kristeleit, Krunal Shah, Víctor Moreno, Paul A. Clarke, Florence I. Raynaud, Gallia G. Levy, Joseph A. Ware, Kathryn Mazina, Ray Lin, Jenny Wu, Jill Fredrickson, Jill M. Spoerke, Mark R. Lackner, Yibing Yan, Lori S. Friedman, Stan B. Kaye, Mika K. Derynck, Paul Workman, Johann S. de Bono

    Published 2014
    Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor–Positive Breast Cancer

    Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor–Po... by Peter Schmid, Sarah E. Pinder, Duncan Wheatley, Jane Macaskill, Charles Zammit, Jennifer J. Hu, R. Jordan Price, Nigel Bundred, Sirwan Hadad, Alice Shia, Shah-Jalal Sarker, Louise Lim, Patrycja Gazińska, Natalie Woodman, Darren Korbie, Matt Trau, Paul N. Mainwaring, Steven Gendreau, Mark R. Lackner, Mika K. Derynck, Timothy R. Wilson, H. EUGENE BUTLER, Gemma Earl, Peter J. Parker, Arnie Purushotham, Alastair M. Thompson

    Published 2016
    Get full text
    Carta
    Save to List
    Saved in:

Search Tools: